An introduction to pembrolizumab (Keytruda®) and its common usage and dosage.👀👀👀

Pembrolizumab is a monoclonal antibody. It is a programmed death receptor-1 (PD-1) blocker. The PD-1 receptor expressed by T cells binds to its ligands PD-L1 and PD-L2, thereby inhibiting T cell proliferation and cytokine production. PD-1 ligands are upregulated in some tumor cells. Signaling in this pathway can help inhibit active T cell immune surveillance of tumors. Pembrolizumab...

Read More

An introduction to Nivolumab (Opdivo®) and its common usage and dosage.(Part 2)👀👀👀

The introduction to Nivolumab (Opdivo®) Part. 2. Nivolumab is recommended for the treatment of a variety of malignancies in children aged 12 years and older.Common Pediatric Usage and Dosage of Nivolumab:Recommended dose of nivolumab monotherapy: Indications Dosage Duration Unresectable or metastatic melanoma For pediatric patients...

Read More

An introduction to Nivolumab (Opdivo®) and its common usage and dosage.(Part 1)👀👀👀

Nivolumab (Opdivo®) is a monoclonal antibody. It binds to the PD-1 receptor, thereby blocking the interaction of the PD-1 receptor with PD-L1 and PD-L2. Immunosuppressive responses mediated by the PD-1 pathway will be blocked (such as tumor immune responses). Nivolumab can be used to treat a variety of malignant tumors in adults. Nivolumab is commonly used in the form...

Read More